Willner & Heller LLC Has $291,000 Stake in Pfizer Inc. (NYSE:PFE)

Willner & Heller LLC cut its position in Pfizer Inc. (NYSE:PFE) by 28.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,067 shares of the biopharmaceutical company’s stock after selling 4,090 shares during the quarter. Willner & Heller LLC’s holdings in Pfizer were worth $291,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in shares of Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the second quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth about $31,000. Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter valued at approximately $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Performance

Shares of PFE traded down $0.18 on Friday, reaching $29.16. 29,617,610 shares of the company’s stock traded hands, compared to its average volume of 37,393,754. The stock’s 50 day simple moving average is $29.04 and its two-hundred day simple moving average is $28.38. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $33.92. The stock has a market cap of $165.24 billion, a PE ratio of -486.00, a PEG ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the previous year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.76%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.